Mineralys: Phase 2 Trial Results for Lorundrostat in Uncontrolled and Treatment-Resistant Hypertension

 

• Lorundrostat, a highly selective aldosterone synthase inhibitor, demonstrated robust, double-digit reduction in systolic blood pressure (BP) with a well-tolerated profile
• Enhanced reduction in systolic BP seen in individuals with elevated body mass index (BMI)
• Robust trial design and results led to lorundrostat being first of new class, aldosterone synthase inhibitors, to start pivotal clinical program in hypertension

https://www.biospace.com/article/releases/mineralys-therapeutics-announces-jama-publication-of-full-target-htn-phase-2-trial-results-for-lorundrostat-in-uncontrolled-and-treatment-resistant-hypertension/